The Scripps Research Institute

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 26661
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 20430
 
  
 
C07K PEPTIDES 13631
 
  
 
C07D HETEROCYCLIC COMPOUNDS 12758
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 8328
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 6739
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 64142
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 5570
 
  
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 35103
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 2075

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0057,570 BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODYSep 12, 17Mar 01, 18[A61K, C07K]
2018/0037,532 RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCTAug 26, 15Feb 08, 18[C07C]
2018/0008,605 PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORSJan 22, 16Jan 11, 18[A61K, C07D]
2017/0349,595 SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USEApr 28, 17Dec 07, 17[A61K, C07H, C07D]
2017/0334,967 TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTORAug 14, 15Nov 23, 17[A61K, C07K]
2017/0292,129 TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCESAug 13, 15Oct 12, 17[C07H, A61K, C12N]
2017/0255,743 SYSTEMS AND METHODS FOR GENOMIC ANNOTATION AND DISTRIBUTED VARIANT INTERPRETATIONMar 26, 15Sep 07, 17[G06F]
2017/0239,296 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLSJan 18, 17Aug 24, 17[A61K, C12N]
2017/0241,984 High-throughput screening for compounds modulating expression of cellular macromoleculesFeb 22, 17Aug 24, 17[A61K, G01N]
2017/0224,653 TLR-INDEPENDENT SMALL MOLECULE ADJUVANTSAug 05, 15Aug 10, 17[A61K, C07D, C07C]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9918959 TLR-independent small molecule adjuvantsAug 05, 15Mar 20, 18[A61K, C07D, C07C]
9920111 Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activityApr 21, 15Mar 20, 18[A61K, C07K]
9921225 Phenyl glyoxal probesMay 20, 16Mar 20, 18[C12Q, C07D, C07C, C07B, G01N]
9909105 Induction of pluripotent cellsMar 03, 15Mar 06, 18[C12N]
9902962 Chimeric polypeptides having targeted binding specificitySep 04, 13Feb 27, 18[C12N]
9896547 Polymerization method and polymers formed therewithApr 11, 17Feb 20, 18[C08G]
9896655 Methods of enhancing cell survival of stem cellsApr 14, 16Feb 20, 18[C12N, C07D]
9879049 Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strainsAug 03, 12Jan 30, 18[A61K, C07K]
9850276 Bidentate-binding modulators of LRRK2 and JNK kinasesMay 22, 14Dec 26, 17[A61K, C07D, C07K]
9833437 Small molecule inhibitor of MYD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposureDec 05, 16Dec 05, 17[A61K, C07D]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0107,275 ENANTIOPURE HAPTENS FOR NICOTINE VACCINE DEVELOPMENTAbandonedMay 19, 15Apr 20, 17[C07D, C07K]
2017/0050,941 NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORSAbandonedJun 21, 16Feb 23, 17[C07D]
2016/0376,563 Methods and Compositions for Treating ObesityAbandonedJul 01, 14Dec 29, 16[C12N]
2016/0368,983 COMPOSITIONS AND METHODS FOR TREATING OBESITYAbandonedJul 01, 14Dec 22, 16[C07K]
2016/0362,478 CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIESAbandonedFeb 10, 15Dec 15, 16[A61K, C07K]
2016/0244,435 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALSAbandonedJun 20, 14Aug 25, 16[A61K, C07D]
2016/0214,946 CATALYSED LIGATION OF AZIDES AND ACETYLENESAbandonedMar 30, 16Jul 28, 16[C07D]
2016/0194,299 COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSISAbandonedMay 22, 14Jul 07, 16[C07D]
2016/0017,058 BISPECIFIC ANTIBODIES AND USES THEREOFAbandonedMar 14, 14Jan 21, 16[C07K]
2015/0376,198 MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIALAbandonedFeb 18, 14Dec 31, 15[C07D]
2015/0246,908 KLF5 MODULATORSAbandonedJul 26, 13Sep 03, 15[C07D]
2015/0238,631 CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOFAbandonedOct 15, 14Aug 27, 15[A61K, C07K]
2015/0167,085 Methods and Systems for Analysis of Organ TransplantationAbandonedSep 09, 14Jun 18, 15[C12Q, G06F]
2015/0126,519 ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOFAbandonedMar 20, 13May 07, 15[A61K, C12Q, C07D]
2015/0045,286 BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGSAbandonedMar 08, 13Feb 12, 15[C07K]
2015/0031,750 TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNFAbandonedMar 12, 13Jan 29, 15[C12N]
2015/0011,431 HUMANIZED ANTIBODIESAbandonedJan 09, 13Jan 08, 15[C07K]
2014/0378,426 Methods and compositions for enhancing visual functionAbandonedJun 20, 14Dec 25, 14[A61K]
2014/0370,545 Reengineering mRNA Primary Structure for Enhanced Protein ProductionAbandonedSep 04, 14Dec 18, 14[C12P]
2014/0328,795 VIRUCIDAL SMALL MOLECULE AND USES THEREOFAbandonedSep 10, 13Nov 06, 14[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.